Takeda Pharmaceutical Company Limited

Mamoru Tobisu

Keiji Kubo

Takahiko Taniguchi

Masaki Kawamura

Yoshiyuki Fukase

Eiji Honda

Masaharu Nakayama

The present invention relates to a thrombin receptor antagonist containing a compound represented by the formula (I) wherein R, Rand Rare each a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group, or an optionally substituted alkoxy, Ris a group represented by the formula &#x2014;NHCOR, &#x2014;NHSOR, &#x2014;NHCON(R)(R), &#x2014;NHCOORor &#x2014;CONHRwherein R, R, R, R, Rand Rare each a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group and the like), ring A is monocyclic aromatic ring optionally further having substituent(s), Rand Rare optionally bonded to each other to form an optionally substituted nitrogen-containing non-aromatic heterocycle, or a salt thereof or a prodrug thereof. The thrombin receptor antagonist of the present invention has a thrombin receptor (particularly PAR-1) antagonistic action and is useful for the prophylaxis or treatment of PAR-1 mediated pathological condition or disease.

Growing community of inventors

Minoh, Japan

Mamoru Tobisu